Ipilimumab- and nivolumab-associated enterocolitis with florid necrotising granulomatous inflammation: a novel manifestation of 'immunomodulatory' enterocolitis

Pathology. 2018 Jun;50(4):466-469. doi: 10.1016/j.pathol.2017.11.094. Epub 2018 May 4.

Authors

David J W Paton¹, Lydia Warburton², Kim Chung³, Tarek M Meniawy⁴, M Priyanthi Kumarasinghe³

Affiliations

¹ PathWest Laboratory Medicine, QE2 Medical Centre, Perth, WA, Australia. Electronic address: [email protected].
² Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
³ PathWest Laboratory Medicine, QE2 Medical Centre, Perth, WA, Australia.
⁴ Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia; School of Medicine and Pharmacology, University of Western Australia, WA, Australia.

PMID: 29735170
DOI: 10.1016/j.pathol.2017.11.094

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents, Immunological / adverse effects*
Enterocolitis, Necrotizing / chemically induced*
Humans
Ipilimumab / adverse effects*
Male
Melanoma / drug therapy*
Nivolumab

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Ipilimumab
Nivolumab